Growth hormone releasing peptides
Your pituitary gland releases growth hormone in pulses, mostly at night, and that output declines with age. Growth hormone releasing peptides — sermorelin, ipamorelin, CJC-1295, tesamorelin — are studied for nudging the body's own pulses rather than replacing the hormone outright.
The articles below cover how each one works, how they differ from one another and from HGH itself, and what the research does and doesn't show. All of them are prescription-only through Promise: a licensed provider reviews every request.
43 articles on this topic
-
Is Sermorelin FDA Approved? Not Since 2009
Geref, the only sermorelin product the United States ever approved, left the market in 2008 and its approvals were withdrawn in 2009 — not over safety. Here is what that means for a prescription today.
-
What Is Sermorelin Used For? A Plain Answer
Sermorelin was approved once, for children who were not growing. Adults are prescribed it today for sleep, body composition and recovery — uses that rest on a handful of small studies.
-
CJC-1295 Ipamorelin for Women: Evidence and Limits
CJC-1295 with ipamorelin may stimulate the growth-hormone axis, but no clinical trial has tested the combination specifically in women. Perimenopause, estrogen route and the limits of body-composition and sleep evidence all matter to the prescribing decision.
-
Does CJC-1295 Ipamorelin Work? Evidence Review
The combination has no clinical trial of its own. Separate studies show that CJC-1295 and ipamorelin can raise growth hormone signals, but they do not establish predictable sleep, recovery, muscle, or fat-loss results from the blend.
-
Does Sermorelin Cause Hair Loss? Evidence Review
Current evidence does not identify hair loss as a sermorelin side effect. Growth hormone and IGF-1 affect follicles, but that biology cannot explain why one person starts shedding.
-
Tesamorelin for Women: Evidence and Menopause
Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.
-
Tesamorelin Injections: Sites, Timing, and Storage
Tesamorelin is injected under the skin once daily. The abdomen, site rotation, timing, device format, and storage instructions all matter—and they are not identical across branded and compounded formulations.
-
FDA Peptide Warning Letters: What They Mean
FDA’s five August 24 letters targeted the way online sellers presented injectable peptides for people—not peptide molecules as a class. Here’s what changed, what didn’t, and how a prescription route differs.
-
Does Tesamorelin Work? What the Trials Show
Tesamorelin reduced visceral abdominal fat in two large phase 3 trials, but those studies involved adults with HIV-associated lipodystrophy. The evidence does not establish it as a general weight-loss medication or promise the same result for every patient.
-
Sermorelin for Men: Testosterone, Muscle & Sleep
Sermorelin can stimulate growth-hormone release when the pituitary responds, but it is not testosterone therapy. Small studies in older men found biochemical changes and mixed body-composition or strength results, with no reliable sleep or recovery benefit established.
-
Sermorelin Tablets: Do Oral Forms Work?
Tablets, troches and rapid-dissolve forms sound simpler than an injection. The unresolved question is whether they deliver intact sermorelin into the bloodstream in a reliable amount.
-
Sermorelin for Weight Loss: What Studies Show
Sermorelin is not a weight-loss drug. It changes growth-hormone signaling, but small older-adult studies found hormone effects without reliable scale-weight loss.
-
Tesamorelin vs CJC-1295: Evidence and Differences
Both peptides signal through the GHRH receptor, but their structures, duration and human evidence differ sharply. The clearest distinction is phase 3 visceral-fat data for tesamorelin versus biomarker studies for CJC-1295.
-
Is Tesamorelin FDA Approved? Not Every Form
Egrifta has an indication-specific approval for adults with HIV and lipodystrophy. Tesamorelin offered here is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation is not FDA-approved.
-
Sermorelin Injections: Sites and Expectations
Sermorelin is injected into the fatty layer beneath the skin, commonly around bedtime. The dose, schedule, site plan, and storage instructions come from the prescriber and dispensing pharmacy—not a universal online protocol.
-
How Long Do Peptides Take to Work?
Peptide timelines range from hours on a lab test to months on a scale. The useful answer depends on the molecule, the outcome being measured and the quality of the evidence behind it.
-
Peptides With Semaglutide: What the Evidence Says
Evidence gaps depend on the specific peptide combined with semaglutide; [cagrilintide–semaglutide has randomized phase 3 trial data](https://pubmed.ncbi.nlm.nih.gov/40544433/), while the combinations discussed here do not. A provider has to judge each compound on its own evidence, risks, and purpose.
-
What Are Peptides? A Plain-English Guide
Peptides are short chains of amino acids that the body uses as signals. The same broad family includes natural hormones, established medicines and experimental compounds, so the name alone says little about evidence or safety.
-
Peptides vs Steroids: What Makes Them Different?
Peptides and anabolic steroids are different molecules with different targets, evidence, risks, and legal status. A peptide is not simply a steroid under a newer name.
-
Tesamorelin for Belly Fat: What the Studies Show
Tesamorelin has reduced visceral abdominal fat in randomized trials, most convincingly in adults with HIV-associated lipodystrophy. That evidence does not make it a general weight-loss drug or a reliable way to shrink the fat just under the skin.
Page 1 of 3 · 43 articles